S&P 500 closes slightly lower as chip stocks slide; Moderna shares buck the trend

U.S. stocks ended lower on Friday, but the pullback was modest at the index level. The Dow and S&P 500 each slipped by less than a tenth of 1%, while the Nasdaq Composite fell by roughly a quarter of 1%, according to a market wrap published by Yahoo Finance.

Chip stocks were the main drag. The report said AI-related semiconductor names declined sharply, weighing on the broader technology complex and contributing to the Nasdaq’s bigger percentage move versus the Dow and S&P 500.

In contrast to the weakness seen across parts of tech, Moderna rallied on the day. The market wrap highlighted Moderna’s stock as one of the notable gainers during the session, even as the broader tape remained cautious and chips fell.

The divergence underscored how single-industry moves can dominate daily performance when investors are focused on a narrow set of themes. In this case, semiconductors tied to AI expectations were under pressure, while investor interest in Moderna appears to have provided a pocket of relative strength.

Moderna, which trades on the Nasdaq under the ticker MRNA, is known for developing messenger RNA (mRNA) medicines. In this delivery model, an mRNA sequence is designed to instruct the body to produce a specific target protein, which is intended to trigger an immune response for vaccines or therapeutic effects for certain conditions. That product platform can sometimes attract attention during broader market risk-offs if investors view its pipeline or catalysts as more idiosyncratic than cyclical.

Sector performance was therefore split. Healthcare-related strength did not fully offset the tech-led decline, but it did show that market moves were not uniform across all groups. The day’s closing pattern suggested that investors were rotating within sectors rather than selling broadly across the board.

What was not disclosed in the Yahoo Finance market wrap was any specific Moderna catalyst for the move, such as earnings commentary, trial results, regulatory updates, or guidance changes. The post framed the action as a market outcome alongside index and chip-stock moves, without detailing the underlying reason for Moderna’s rally.

Going into the next session, traders are likely to watch whether chip weakness extends or stabilizes, since it is closely tied to the Nasdaq’s direction. At the stock level, Moderna’s near-term performance will also depend on whether the day’s strength proves durable or was driven by broader market rotation rather than a company-specific development.